Physician profile
Matthew Koehler
NPI 1164652178
$2,145.14
in general payments reported to CMS, 2019-2025
15 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2021: $15.93 · 2022: $122 · 2023: $448 · 2024: $521 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,551.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $539.31 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Glaukos Corporation | $265.16 | 2025 | Idosetr |
| Alcon Vision LLC | $232.44 | 2022-2025 | Rocklatan, Unity |
| Allergan, INC. | $168.59 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $163.39 | 2019 | |
| Oyster Point Pharma, INC. | $157.34 | 2023-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $130.44 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.30 | 2019 | |
| Dompe US, INC. | $120.22 | 2024-2025 | Oxervate |
| Abbvie INC. | $96.18 | 2023-2025 | |
| Rayner Intraocular Lenses Limited | $55.51 | 2023 | Rayone Aspheric, Rayone Spheric, Rayone Emv |
| Sun Pharmaceutical Industries INC. | $50.19 | 2024 | |
| Tearlab Corp | $14.29 | 2023 | Tearlab Osmolarity System |
| Shire North American Group INC | $13.50 | 2019 | |
| Harrow Eye, LLC | $13.28 | 2024 | Iheezo, Triesence |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Koehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.